A bioequivalent generic, Sacutan tablets (Sacubitril/Valsartan) is indicated to reduce the risk of cardiovascular death and hospitalisation for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction
MSN Group, a research-based fully integrated pharmaceutical company based out of Hyderabad, has announced the relaunch of Sacubitril/Valsartan tablets, 50 mg, 100 mg and 200 mg for Heart Failure with Reduced Ejection Fraction (HFrEF) under the brand name Sacutan. This time, the company is offering the product at the most affordable price of Rs 14 for a dose of 50mg, Rs 21 for a dose of 100 mg, and Rs 35 for a dose of 200mg. The mentioned price is 50 per cent lower than the innovator and in-licensed brands, and 20 per cent lower than the new generic launches by other Indian players.
MSN Labs has made a difference in cardiac care through the introduction of the PAH group of drugs and hyponatremia addressing the therapy gaps. MSN Group also revolutionised the cost affordability of various new-generation anti-diabetic drugs through the introduction of Dapagliflozin, Sitagliptin and a few more.
“The launch of Sacutannot only reflects our commitment to bring new and advanced therapies within an affordable reach but also our capability of doing it swiftly and consistently. Given the alarming rise in heart failures, we are proud that we are among the first few to launch such an important life-saving drug, proven to reduce the risk of cardiovascular hospitalisation and death associated with heart failure with reduced ejection fraction (HFrEF),” MSN Group commented.
